Salarius Pharmaceuticals Stock In The News

SLRX Stock  USD 1.45  0.07  4.61%   
The analysis of Salarius Pharmaceuticals' news coverage and content from conventional and social sources shows investors' indifference towards Salarius Pharmaceuticals. The specific impact of Salarius Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Salarius Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Salarius Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out Salarius Pharmaceuticals Backtesting and Salarius Pharmaceuticals Hype Analysis.
For more information on how to buy Salarius Stock please use our How to Invest in Salarius Pharmaceuticals guide.

Salarius Pharmaceuticals Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
https://www.globenewswire.com/news-release/2023/11/07/2775117/0/en/Salarius-Completes-FDA-Type-B-Meeting-for-Seclidemstat-Ewing-Sarcoma-Development-Program.html
 Neutral
Macroaxis News: globenewswire.com
Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update
https://www.globenewswire.com/news-release/2023/08/10/2723137/0/en/Salarius-Pharmaceuticals-Reports-Second-Quarter-2023-Financial-Results-and-Provides-a-Business-Update.html
 Neutral
Macroaxis News: globenewswire.com
Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources
https://www.globenewswire.com/news-release/2023/08/08/2721166/0/en/Salarius-Pharmaceuticals-Announces-Plans-to-Explore-Strategic-Alternatives-and-Implement-Measures-to-Extend-its-Resources.html
 Neutral
Macroaxis News: globenewswire.com
Salarius Pharmaceuticals Receives FDA Cl...
https://www.globenewswire.com/news-release/2023/07/11/2702641/0/en/Salarius-Pharmaceuticals-Receives-FDA-Clearance-of-SP-3164-Investigational-New-Drug-Application-to-Begin-a-Phase-1-Clinical-Trial-in-Relapsed-Refractory-Non-Hodgkin-Lymphoma-Patien.html
 Neutral
Macroaxis News: globenewswire.com
Salarius Pharmaceuticals Presents SP-316...
https://www.globenewswire.com/news-release/2023/06/12/2686231/0/en/Salarius-Pharmaceuticals-Presents-SP-3164-Targeted-Protein-Degrader-Preclinical-Data-at-the-European-Hematology-Association-2023-Hybrid-Congress.html
 Neutral
Macroaxis News: globenewswire.com
Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
https://www.globenewswire.com/news-release/2023/05/16/2670425/0/en/Salarius-Pharmaceuticals-Announces-Closing-of-6-Million-Private-Placement-Priced-At-the-Market-Under-Nasdaq-Rules.html
 Neutral
Macroaxis News: globenewswire.com
Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
https://www.globenewswire.com/news-release/2023/05/12/2667739/0/en/Salarius-Pharmaceuticals-Announces-6-Million-Private-Placement-Priced-At-the-Market-Under-Nasdaq-Rules.html
 Neutral
Macroaxis News: globenewswire.com
Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update
https://www.globenewswire.com/news-release/2023/05/11/2666688/0/en/Salarius-Pharmaceuticals-Reports-First-Quarter-2023-Financial-Results-and-Provides-a-Business-Update.html
 Neutral
Macroaxis News: globenewswire.com
FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma
https://www.globenewswire.com/news-release/2023/05/09/2664364/0/en/FDA-Removes-Partial-Clinical-Hold-on-Salarius-Pharmaceuticals-Phase-1-2-Clinical-Trial-with-Seclidemstat-in-Patients-with-Ewing-Sarcoma.html
 Neutral
Macroaxis News: globenewswire.com
Salarius Pharmaceuticals Reports No Adve...
https://www.globenewswire.com/news-release/2023/05/01/2658293/0/en/Salarius-Pharmaceuticals-Reports-No-Adverse-Safety-Signals-from-Two-Good-Laboratory-Practice-Toxicology-Studies-with-its-Targeted-Protein-Degrader-SP-3164.html
 Neutral

Salarius Pharmaceuticals Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Salarius and other traded companies coverage with news coverage. We help investors stay connected with Salarius headlines for the 29th of November to make an informed investment decision based on correlating the impacts of news items on Salarius Stock performance. Please note that trading solely based on the Salarius Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.
Salarius Pharmaceuticals' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Salarius Pharmaceuticals investors visualize upcoming and past events in order to time the market based on Salarius Pharmaceuticals noise-free hype analysis.
Salarius Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Salarius earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Salarius Pharmaceuticals that are available to investors today. That information is available publicly through Salarius media outlets and privately through word of mouth or via Salarius internal channels. However, regardless of the origin, that massive amount of Salarius data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Salarius Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Salarius Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Salarius Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Salarius Pharmaceuticals alpha.

Salarius Largest EPS Surprises

Earnings surprises can significantly impact Salarius Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2023-08-10
2023-06-30-1.3-1.43-0.1310 
2023-05-11
2023-03-31-2.5-2.230.2710 
2021-08-05
2021-06-30-1.42-1.75-0.3323 
2022-08-05
2022-06-30-2.62-2.250.3714 
2021-11-04
2021-09-30-1.62-2.0-0.3823 
2023-11-09
2023-09-30-1.2-0.650.5545 
View All Earnings Estimates

Salarius Pharmaceuticals Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Salarius Pharmaceuticals Stock. Current markets are slightly bullish. About 51% of major world exchanges and indexes are currently up. See today's market update for more information.
Gurufocus Stories at Macroaxis
15th of November 2024
ARMISTICE CAPITAL, LLC Increases Stake in Salarius Pharmaceuticals Inc
at gurufocus.com 
Google News at Macroaxis
14th of October 2024
SLRX stock touches 52-week low at 1.3 amid market challenges - Investing.com
at news.google.com 
Google News at Macroaxis
19th of September 2024
Salarius Pharmaceuticals Stock Quotes, Forecast and News Summary - Benzinga
at news.google.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Salarius Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Salarius Pharmaceuticals' short interest history, or implied volatility extrapolated from Salarius Pharmaceuticals options trading.

Additional Tools for Salarius Stock Analysis

When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.